Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

por Maitland, Michael L., Piha-Paul, Sarina, Falchook, Gerald, Kurzrock, Razelle, Nguyen, Ly, Janisch, Linda, Karovic, Sanja, McKee, Mark, Hoening, Elizabeth, Wong, Shekman, Munasinghe, Wijith, Palma, Joann, Donawho, Cherrie, Lian, Guinan K., Ansell, Peter, Ratain, Mark J., Hong, David
Publicado 2018

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

por Jones, Robin L., Ratain, Mark J., O’Dwyer, Peter J., Siu, Lillian L., Jassem, Jacek, Medioni, Jacques, DeJonge, Maja, Rudin, Charles, Sawyer, Michael, Khayat, David, Awada, Ahmad, de Vos-Geelen, Judith M.P.G.M., Evans, T.R. Jeffry, Obel, Jennifer, Brockstein, Bruce, DeGreve, Jacques, Baurain, Jean-Francois, Maki, Robert, D’Adamo, David, Dickson, Mark, Undevia, Samir, Geary, David, Janisch, Linda, Bedard, Philippe L., Razak, Albiruni R. Abdul, Kristeleit, Rebecca, Vitfell-Rasmussen, Joanna, Walters, Ian, Kaye, Stan B., Schwartz, Gary
Publicado 2019